Skip to content

Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management

Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management by Mobile Acute Pain Team

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02690597
Acronym
ANXYDOL
Enrollment
55
Registered
2016-02-24
Start date
2015-02-28
Completion date
2016-12-31
Last updated
2018-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Pain

Keywords

Anxiety analogic visual scale, Pain, State Trait Inventory anxiety scale, Anxiety

Brief summary

Screening of anxiogenic part of pain is an imperative during a medical pain consultation. The actual tools for evaluation of this specific part are complex and time consuming. To date, it lacked a reliable and reproductive tool to quickly evaluate anxiety of patient in pain. The purpose of this study is to demonstrate the pertinence and validity of anxiety analogic visual scale by comparison with the actual reference the self-assessment questionnaire State Trait Inventory Anxiety Y-A form.

Interventions

OTHERAnxiety visual analog scale

Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed and dated informed consent * Male or female aged from ≥ 18 years old * Perfect patient ability to understand and write French * Patient with a pain threshold permitting a initial medication free consultation and completion of anxiety surveys.

Exclusion criteria

* Inability of patient to understand the study procedures and thus inability to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of validity of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with anxiety analogic visual scale scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of validity of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with State Trait of anxiety Y-A form scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of pertinence of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with anxiety analogic visual scale scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of pertinence of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with State Trait of anxiety Y-A form scoreBaselineThe patient's inclusion take place during the only study participation day of the patient

Secondary

MeasureTime frameDescription
Evaluation of pain consultation impact on anxiety part of pain as assessed by anxiety levels obtained with State Trait of anxiety Y-A form scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of pain consultation impact on anxiety part of pain as assessed by anxiety levels obtained with anxiety analogic visual scale scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of clinical utility of anxiety analogic visual scale in nursing care as assessed by anxiety levels obtained with State Trait of anxiety Y-A form scoreBaselineThe patient's inclusion take place during the only study participation day of the patient
Evaluation of clinical utility of anxiety analogic visual scale in nursing care as assessed by anxiety levels anxiety analogic visual scale scoreBaselineThe patient's inclusion take place during the only study participation day of the patient

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026